ALI HEALTH (00241.HK) 0.000 (0.000%) Short selling $153.16M; Ratio 34.469% launched the "Hydrion" app, positioning it as an early AI pioneer targeting doctors, in collaboration with The BMJ to provide evidence-based clinical decision support, Jefferies said in its report. Initial product testing shows strong usability, a low hallucination rate and robust clinical reasoning. Management expects to invest RMB200-300 million annually in AI R&D during FY2027-29, targeting 2 million MAUs within three years and aiming for "Hydrion" to achieve breakeven in 2029.Related NewsALI HEALTH (00241.HK) and JD HEALTH (06618.HK) Drop 3%-5% as CLSA Says Impact from GLP-1 Online Sales Restrictions Limited; Nomura: Market OverreactedAs a leading B2C participant, ALI HEALTH's internet hospital workflow has been officially authorized and is largely unaffected by recent news regarding tightened GLP-1 prescription restrictions in Jiangxi and Shanghai. The broker lowered its TP on ALI HEALTH from HKD6 to HKD5.3 to reflect uncertainties such as commercialization pace, but maintained its Buy rating.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)
AASTOCKS Financial News